Biomarin Pharmaceutical Income Statement (2009-2026) | BMRN

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	501.69M	408.74M	449.81M	519.36M	533.80M	505.34M	537.54M	596.41M	595.27M	581.33M	646.21M	648.83M	712.03M	745.74M	747.31M	745.14M	825.41M	776.13M	874.57M	766.21M
Cost of Revenue (Quarter)	127.06M	103.54M	119.75M	116.97M	123.13M	116.29M	146.64M	135.47M	130.62M	128.04M	137.93M	125.18M	130.46M	188.46M	136.14M	151.56M	150.09M	140.09M	275.71M	195.00M
Gross Profit (Quarter)	374.63M	305.20M	330.06M	402.39M	410.67M	389.06M	390.89M	460.94M	464.66M	453.29M	508.28M	523.65M	581.57M	557.28M	611.17M	593.59M	675.32M	636.05M	598.86M	571.21M
Operating items
Amortization - Intangibles (Quarter)	17.69M	17.22M	17.29M	17.61M	16.50M	16.83M	16.26M	15.67M	15.62M	15.68M	15.24M	14.30M	14.30M	5.01M	9.65M	4.85M	4.85M	4.85M	4.85M	4.48M
Research & Development (Quarter)	161.11M	157.87M	161.09M	160.84M	158.19M	157.83M	172.75M	171.85M	177.36M	191.31M	206.25M	204.99M	183.79M	184.90M	173.51M	158.73M	161.31M	409.48M	192.41M	178.80M
Selling, General & Administrative (Quarter)	184.16M	183.33M	217.56M	194.62M	196.84M	216.82M	214.97M	211.02M	206.10M	215.77M	259.51M	225.91M	263.03M	253.48M	266.61M	206.12M	232.28M	268.42M	446.21M	258.29M
Other Operating Expenses (Quarter)	1.83M	9.10M	-10.44M	-1.15M			-9.55M	-13.89M		-0.82M	-19.90M	1.27M	-4.53M	5.46M	-6.87M		4.83M		1.02M	3.96M
Operating Expenses (Quarter)	490.02M	461.96M	515.69M	382.03M	494.65M	507.76M	550.63M	534.01M	529.71M	550.80M	618.93M	560.37M	591.58M	631.85M	585.91M	521.25M	548.52M	822.83M	919.17M	636.57M
Operating Income (Quarter)	11.67M	-53.22M	-65.88M	137.33M	39.15M	-2.42M	-13.09M	62.40M	65.57M	30.52M	27.28M	88.46M	120.45M	113.89M	161.41M	223.89M	276.89M	-46.69M	-44.61M	129.64M
EBIT (Quarter)	11.67M	-53.22M	-65.88M	137.33M	39.15M	-2.42M	-13.09M	62.40M	65.57M	30.52M	27.28M	88.46M	120.45M	113.89M	161.41M	223.89M	276.89M	-46.69M	-44.61M	129.64M
Non-operating items
Interest & Investment Income (Quarter)	4.47M	1.83M	1.75M	1.82M	2.50M	5.00M	8.71M	11.94M	12.61M	15.74M	18.04M	19.36M	19.79M	18.05M	17.68M	19.01M	18.83M	17.85M	19.21M	22.56M
Net income details
EBT (Quarter)	14.16M	-46.16M	-66.57M	134.19M	34.85M	-1.90M	-17.56M	56.76M	70.81M	41.67M	19.33M	105.55M	132.14M	134.44M	169.64M	238.09M	297.87M	-26.32M	-27.15M	141.20M
Tax Provisions (Quarter)	1.22M	-9.67M	-8.68M	13.39M	7.19M	4.75M	-17.31M	5.91M	14.77M	1.29M	-1.05M	16.89M	24.96M	28.36M	44.70M	52.40M	57.34M	4.42M	19.42M	35.68M
Profit After Tax (Quarter)	12.94M	-36.49M	-57.90M	120.80M	27.66M	-6.65M	-0.25M	50.85M	56.04M	40.38M	20.38M	88.66M	107.17M	106.08M	124.94M	185.69M	240.53M	-30.74M	-46.57M	105.53M
Equity Income (Quarter)	-0.17M	0.18M
Income from Continuing Operations (Quarter)	12.94M	-36.49M	-57.90M	120.80M	27.66M	-6.65M	-0.25M	50.85M	56.04M	40.38M	20.38M	88.66M	107.17M	106.08M	124.94M	185.69M	240.53M	-30.74M	-46.57M	105.53M
Consolidated Net Income (Quarter)	12.94M	-36.49M	-57.90M	120.80M	27.66M	-6.65M	-0.25M	50.85M	56.04M	40.38M	20.38M	88.66M	107.17M	106.08M	124.94M	185.69M	240.53M	-30.74M	-46.57M	105.53M
Income towards Parent Company (Quarter)	12.94M	-36.49M	-57.90M	120.80M	27.66M	-6.65M	-0.25M	50.85M	56.04M	40.38M	20.38M	88.66M	107.17M	106.08M	124.94M	185.69M	240.53M	-30.74M	-46.57M	105.53M
Net Income towards Common Stockholders (Quarter)	12.94M	-36.49M	-57.90M	120.80M	27.66M	-6.65M	-0.25M	50.85M	56.04M	40.38M	20.38M	88.66M	107.17M	106.08M	124.94M	185.69M	240.53M	-30.74M	-46.57M	105.53M
Additional items
EPS (Basic) (Quarter)	0.07	-0.20	-0.32	0.66	0.15	-0.04	-0.01	0.27	0.30	0.21	0.11	0.47	0.56	0.56	0.66	0.97	1.25	-0.16	-0.24	0.55
EPS (Weighted Average and Diluted) (Quarter)	0.07	-0.20	-0.32	0.63	0.15	-0.04	0.00	0.27	0.29	0.21	0.10	0.46	0.55	0.55	0.65	0.95	1.23	-0.16	-0.24	0.54
Shares Outstanding (Weighted Average) (Quarter)	182.31M	182.62M	182.85M	183.99M	184.71M	185.01M	185.27M	186.67M	187.95M	188.22M	187.83M	188.87M	190.11M	189.81M	190.03M	190.97M	191.91M	191.64M	191.79M	192.50M
Shares Outstanding (Diluted Average) (Quarter)	185.09M	183.21M	182.85M	194.89M	191.10M	192.25M	188.96M	194.36M	194.76M	191.17M	191.59M	199.26M	200.14M	196.68M	196.71M	196.47M	196.64M	196.89M	197.39M	197.67M
EBITDA (Quarter)	7.00M	-25.32M	-65.88M	105.49M	47.01M	5.62M	-13.09M	44.00M	48.15M	65.25M	27.28M	116.40M	135.02M	83.93M	161.41M	143.18M	176.82M	-20.12M	-44.61M	114.76M
Interest Expenses (Quarter)	3.82M	3.87M	3.85M	3.81M	3.86M	4.68M	3.63M	3.70M	3.75M	3.78M	6.10M	3.55M	3.57M	2.97M	2.58M	2.86M	2.68M	2.58M	2.78M	9.57M
Tax Rate (Quarter)	8.58%	20.94%	13.03%	9.98%	20.62%	-249.37%	98.58%	10.40%	20.86%	3.10%	-5.42%	16.00%	18.89%	21.10%	26.35%	22.01%	19.25%	-16.79%	-71.52%	25.27%

Research Tools

Biomarin Pharmaceutical Income Statement (2009-2026) | BMRN

Create an account

Sign In

Reset Password